

Leonard Lothstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11381412/publications.pdf>

Version: 2024-02-01

24
papers

591
citations

567281

15
h-index

677142

22
g-index

24
all docs

24
docs citations

24
times ranked

673
citing authors

#	ARTICLE	IF	CITATIONS
1	ATM and the Catalytic Subunit of DNA-Dependent Protein Kinase Activate NF- κ B through a Common MEK/Extracellular Signal-Regulated Kinase/p90 rsk Signaling Pathway in Response to Distinct Forms of DNA Damage. <i>Molecular and Cellular Biology</i> , 2004, 24, 1823-1835.	2.3	122
2	Anthracycline drug targeting: cytoplasmic versus nuclear – a fork in the road. <i>Drug Resistance Updates</i> , 2001, 4, 169-177.	14.4	67
3	Phosphorylation of mitochondrial phospholipid scramblase 3 by protein kinase C- β induces its activation and facilitates mitochondrial targeting of tBid. <i>Journal of Cellular Biochemistry</i> , 2007, 101, 1210-1221.	2.6	52
4	The release of 40S hnRNP particles by brief digestion of HeLa nuclei with micrococcal nuclease. <i>Nucleic Acids Research</i> , 1980, 8, 3639-3658.	14.5	37
5	Interferon-resistant Daudi Cell Line with a Stat2 Defect Is Resistant to Apoptosis Induced by Chemotherapeutic Agents. <i>Journal of Biological Chemistry</i> , 2009, 284, 27808-27815.	3.4	26
6	Protection from Doxorubicin-Induced Cardiomyopathy Using the Modified Anthracycline N-Benzyladriamycin-14-valerate (AD 198). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 223-230.	2.5	26
7	N-Benzyladriamycin-14-Valerate (AD198) Induces Apoptosis through Protein Kinase C- β -Induced Phosphorylation of Phospholipid Scramblase 3. <i>Cancer Research</i> , 2005, 65, 10016-10023.	0.9	24
8	Involvement of PKC delta (PKC δ) in the resistance against different doxorubicin analogs. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 577-587.	2.5	23
9	Expression of phenotypic traits following modulation of colchicine resistance in J774.2 cells. <i>Journal of Cellular Physiology</i> , 1986, 127, 253-260.	4.1	22
10	Circumvention of Nuclear Factor κ B-Induced Chemoresistance by Cytoplasmic-Targeted Anthracyclines. <i>Molecular Pharmacology</i> , 2004, 65, 1038-1047.	2.3	19
11	N-Benzyladriamycin-14-valerate (AD 198): A Non-Cardiotoxic Anthracycline That Is Cardioprotective through PKC- μ Activation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 323, 658-664.	2.5	19
12	Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 469-81.	4.1	19
13	Interaction of the novel anthracycline antitumor agent N-benzyladriamycin-14-valerate with the C1-regulatory domain of protein kinase C: structural requirements, isoform specificity, and correlation with drug cytotoxicity. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 483-92.	4.1	19
14	Cytotoxicity and intracellular biotransformation of N-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length. <i>Anti-Cancer Drugs</i> , 1998, 9, 58-66.	1.4	17
15	N-benzyladriamycin-14-valerate (AD 198) activates protein kinase C- β holoenzyme to trigger mitochondrial depolarization and cytochrome c release independently of permeability transition pore opening and Ca ²⁺ influx. <i>Anti-Cancer Drugs</i> , 2006, 17, 495-502.	1.4	16
16	Hydroxylation at C-3 of doxorubicin alters the selected phenotype of cellular drug resistance. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1995, 5, 1807-1812.	2.2	15
17	Molecular Models of N-Benzyladriamycin-14-valerate (AD 198) in Complex with the Phorbol Ester-Binding C1b Domain of Protein Kinase C- β . <i>Journal of Medicinal Chemistry</i> , 2001, 44, 1028-1034.	6.4	15
18	The Composition and General Topology of RNA and Protein in Monomer 40 S Ribonucleoprotein Particles. , 1981, , 49-87.		13

#	ARTICLE	IF	CITATIONS
19	Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288). <i>Biochemical Pharmacology</i> , 2000, 60, 1621-1628.	4.4	12
20	N-Benzyladriamycin-14-valerate (AD 198) cytotoxicity circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity. <i>Leukemia Research</i> , 2007, 31, 1085-1095.	0.8	10
21	Multidrug Resistance in the Mouse Macrophage-Like Cell Line J774.2. , 1988, , 223-242.		6
22	P-glycoprotein overexpression in mouse cells does not correlate with resistance to N-benzyladriamycin-14-valerate (AD 198). <i>Anti-Cancer Drugs</i> , 1994, 5, 623-633.	1.4	5
23	Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies. <i>Pharmaceutics</i> , 2018, 10, 50.	4.5	5
24	Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo. <i>Oncology Research</i> , 2020, 28, 451-465.	1.5	2